Compare PXED & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | PCRX |
|---|---|---|
| Founded | 1976 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.1M | 949.9M |
| IPO Year | 2025 | 2010 |
| Metric | PXED | PCRX |
|---|---|---|
| Price | $28.34 | N/A |
| Analyst Decision | Buy | |
| Analyst Count | 7 | |
| Target Price | $44.29 | N/A |
| AVG Volume (30 Days) | 71.8K | N/A |
| Earning Date | 04-07-2026 | 09-06-2026 |
| Dividend Yield | 3.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 1.69 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $4.49 | N/A |
| P/E Ratio | $17.73 | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.52 | N/A |
| 52 Week High | $38.19 | N/A |
| Indicator | PXED | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.60 | 62.77 |
| Support Level | $29.24 | $21.97 |
| Resistance Level | $31.32 | $26.94 |
| Average True Range (ATR) | 0.88 | 0.66 |
| MACD | 0.33 | 0.26 |
| Stochastic Oscillator | 90.44 | 93.15 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.